These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry. Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ; Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026 [TBL] [Abstract][Full Text] [Related]
10. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging. Havekes B; Lai EW; Corssmit EP; Romijn JA; Timmers HJ; Pacak K Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):419-29. PubMed ID: 19088695 [TBL] [Abstract][Full Text] [Related]
11. High-Specific-Activity- Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867 [TBL] [Abstract][Full Text] [Related]
12. I-131 metaiodobenzylguanidine therapy is a significant treatment option for pheochromocytoma and paraganglioma. Zhang X; Wakabayashi H; Kayano D; Inaki A; Kinuya S Nuklearmedizin; 2022 Jun; 61(3):231-239. PubMed ID: 35668668 [TBL] [Abstract][Full Text] [Related]
13. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063 [TBL] [Abstract][Full Text] [Related]
14. Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma. Sudbrock F; Schmidt M; Simon T; Eschner W; Berthold F; Schicha H Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1279-90. PubMed ID: 20179922 [TBL] [Abstract][Full Text] [Related]
15. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115 [TBL] [Abstract][Full Text] [Related]
16. Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma. Carrasquillo JA; Chen CC; Jha A; Pacak K; Pryma DA; Lin FI J Nucl Med; 2021 Sep; 62(9):1192-1199. PubMed ID: 34475242 [TBL] [Abstract][Full Text] [Related]
17. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study. Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708 [TBL] [Abstract][Full Text] [Related]
18. Proposed MIBG Scan-Based Tumor Response Criteria of High-Specific-Activity 131 I-MIBG Therapy in Metastatic Pheochromocytoma/Paraganglioma. Lu Y; Xu G; Jimenez C Clin Nucl Med; 2023 Apr; 48(4):320-323. PubMed ID: 36758558 [TBL] [Abstract][Full Text] [Related]
19. Radioiodinated metaiodobenzylguanidine treatment of neuroendocrine tumors in adults. Postema EJ; McEwan AJ Cancer Biother Radiopharm; 2009 Oct; 24(5):519-25. PubMed ID: 19877881 [TBL] [Abstract][Full Text] [Related]
20. Nuclear medicine therapy of pheochromocytoma and paraganglioma. Troncone L; Rufini V Q J Nucl Med; 1999 Dec; 43(4):344-55. PubMed ID: 10731785 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]